NCT07217704 2026-03-16
FAPI-GO
SOFIE
Phase 3 Recruiting
Clinical Trials
20 trialsNCT05152147 2026-02-27
HERIZON-GEA-01
Jazz Pharmaceuticals
Phase 3 Active not recruiting
NCT07431281 2026-02-24
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
AstraZeneca
Phase 3 Recruiting
NCT01196390 2026-02-18
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT06964568 2026-02-10
CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC
Fudan University
Phase 3 Recruiting
NCT04871412 2026-01-30
POISE
Ottawa Hospital Research Institute
Phase 3 Recruiting
NCT04821778 2026-01-21
Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3 Recruiting
NCT04821843 2026-01-21
Neoadjuvant Treatment Modalities in Esophageal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3 Recruiting
NCT07332221 2026-01-12
Application of Toripalimab as Adjuvant Therapy After Esophageal Cancer Surgery: A Multicenter Clinical Trial
Henan Cancer Hospital
Phase 3 Not yet recruiting
NCT06676449 2026-01-07
TDLN-sparing RT Plus Immunotherapy and Chemotherapy in Locally Advanced ESCC
Fudan University
Phase 3 Recruiting
NCT07306663 2025-12-29
ESO-Nanjing7
Jiangsu Cancer Institute & Hospital
Phase 3 Active not recruiting
NCT06914011 2025-12-03
MRD2START
Asan Medical Center
Phase 3 Not yet recruiting
NCT04540211 2025-10-28
SKYSCRAPER-08
Hoffmann-La Roche
Phase 3 Completed
NCT07211009 2025-10-07
Patient-Reported Symptom Care Versus Usual Care After Esophageal Cancer Surgery: A Single-Center Phase 3 Randomized Trial
Sichuan University
Phase 3 Not yet recruiting
NCT07177794 2025-09-17
EC-CRT-008
Sun Yat-sen University
Phase 3 Not yet recruiting
NCT00680901 2025-08-07
LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib
Novartis
Phase 3 Completed
NCT05357846 2025-06-12
PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)
Sun Yat-sen University
Phase 3 Recruiting
NCT04415853 2025-05-18
Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer
Sunshine Lake Pharma Co., Ltd.
Phase 3 Recruiting
NCT04513418 2025-05-14
POINT
Ruijin Hospital
Phase 3 Recruiting
NCT00357682 2025-05-01
AspECT
University of Oxford
Phase 3 Completed